TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Isradipine Enhancement of Virtual Reality Cue Exposure for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 18-65 years old;~2. Willing and able to provide informed consent, attend all study visits, and comply with the protocol;~3. Daily smoker for at least one year; and~4. Currently smoke an average of at least 5 cigarettes per day.~Exclusion Criteria:~1. Current diagnosis of a psychotic, eating, developmental or bipolar disorder, or significant suicide risk;~2. Current treatment for smoking cessation or use of other nicotine products, including e-cigarettes;~3. Exclusion criteria related to isradipine administration: (a) known allergy or sensitivity to isradipine, (b) hypertension, (c) congestive heart failure, (d) any type of liver disease, (e) current pregnancy, (f) women of childbearing potential who are not using medically accepted forms of contraception, (g) current use of Rifampin, which decreases the availability of calcium channel blockers, or of Tagamet, which can increase hypotensive effects and inhibit hepatic metabolism of isradipine, (h) any other significant medical condition that increases risk, as determined by the study physician;~4. Significant vision problems that would prevent engagement with the 360° video environment; and~5. Past six month substance use disorder, other than nicotine use disorder, assessed by structured interview.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- isradipine (Type: EXPERIMENTAL): Participants will receive 15mg of immediate release isradipine.
- placebo (Type: PLACEBO_COMPARATOR): Participants will receive a placebo pill identical in appearance to isradipine.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of PF-05280014 [Trastuzumab-Pfizer] Or Herceptin® [Trastuzumab-EU] Plus Paclitaxel In HER2 Positive First Line Metastatic Breast Cancer Treatment (REFLECTIONS B327-02)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of breast cancer.~* Presence of metastatic disease.~* Documentation of HER2 gene amplification or overexpression.~* Available tumor tissue for central review of HER2 status.~* At least 1 measurable lesion as defined by RECIST 1.1.~* Eastern Cooperative Oncology Group status of 0 to 2.~* Left ventricular ejection fraction within institutional range of normal, measured by either two dimensional echocardiogram or multigated acquisition scan.~Exclusion Criteria:~* Relapse within 1 year of last dose of previous adjuvant (including neoadjuvant) treatment (except endocrine therapy) and within 1 year before randomization.~* Prior systemic therapy for metastatic disease (except endocrine therapy).~* Prior cumulative dose of doxorubicin of \>400 mg/m2, epirubicin dose \>800 mg/m\^2, or the equivalent dose for other anthracyclines or derivatives (eg, 72 mg/m\^2 of mitoxantrone). If the patient has received more than one anthracycline, then the cumulative dose must not exceed the equivalent of 400 mg/m\^2 of doxorubicin.~* Inflammatory breast cancer.~* Active uncontrolled or symptomatic central nervous system metastases.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PF-05280014 (Type: EXPERIMENTAL): None
- Herceptin® (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Female or male patients aged between 18 to 65 years~* Renal biopsy was used to diagnose IgA nephropathy~* Patients with 24h proteinuria 3.5g and serum albumin concentration lower than 30g/L~Exclusion Criteria:~* Patients with serum creatinine ≥ 3 mg/dl or eGFR \< 30ml/min per 1.73 m2~* urine RBC \> 1 million/ml~* Patients who have received treatment of enough steroids for more than 12 weeks~* patients with secondary IgA~* Patients who have impaired liver function,with ALT/GPT or AST/GOT twice more than the normal upper limit or who have active hepatitis~* Patients with 2 type diabetes or obesity, whose BMI is more than 28kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Prednisone or Prednisolone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes in male or female patients~* Between 18 and 75 years of age~* With a HbA1c greater than or equal to 7.5% and less than 10.5% at randomization~Exclusion Criteria:~* Type 1 diabetics or type 2 diabetics currently on insulin therapy~* Patients unwilling or unable to discontinue their anti-diabetic medication(s)~* History of ketoacidosis~* History of therapy with rosiglitazone, troglitazone, pioglitazone

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rehabilitation of Executive Functioning in Veterans With PTSD and Mild TBI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of PTSD~* History of mild TBI, including concussion \> 6 months ago~* Cognitive difficulties affecting daily functioning~* Age 18-75~* Veteran~* At least 12th grade education or equivalent~Exclusion Criteria:~* Amnesic/Severe memory problems~* Active Substance Abuse/Dependence~* Medical condition that may affect mental status/disrupt study participation~* Active psychotropic medication changes~* Participation in evidence-based PTSD treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- GOALS (Goal-Oriented Attentional Regulation) (Type: EXPERIMENTAL): Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
- EDU (Brain Health Education) (Type: ACTIVE_COMPARATOR): Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Study Comparing the Efficacy and Safety of Varenicline Tartrate to Placebo in Smoking Cessation When Subjects Are Allowed to Set Their Own Quit Date

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men and women~* 18 to 75 yrs old~* Motivated to stop smoking~* Smoke at least 10 cigarettes/day~Exclusion Criteria:~* Active psychiatric disease~* Severe or unstable cardiovascular or pulmonary disease~* Current or recent treatment to stop smoking~* Previous use of varenicline

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- placebo (Type: PLACEBO_COMPARATOR): None
- varenicline (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* \>=40 years of age~* diagnosed COPD with symptoms \>= 2 years~* pre-bronchodilatory FEV1 \<=50% of PN~Exclusion Criteria:~* Current respiratory tract disorder other than COPD~* history of asthma or rhinitis~* significant or unstable cardiovascular disorder

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Symbicort then Formoterol then Placebo (Type: EXPERIMENTAL): Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
- Formoterol then Symbicort then Placebo (Type: EXPERIMENTAL): Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily, then Placebo, 1 inhalation twice daily
- Placebo then Formoterol then Symbicort (Type: PLACEBO_COMPARATOR): Placebo, 1 inhalation twice daily, then Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily, then Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms, 1 inhalation twice daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of CCX282-B in Subjects With Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* moderate to severe Crohn's Disease~* CDAI 250-450~* CRP \>7.5~* signed written informed consent~Key Exclusion Criteria:~* \> 100 cm of small bowel resected~* ileostomy, colostomy or rectal pouch~* diagnosis of ulcerative colitis or indeterminate colitis~* evidence of short bowel syndrome requiring enteral or parenteral supplementation or total parenteral nutrition~* hepatitis B, C or HIV infection~* history of infection requiring IV antibiotics~* serious or GI infection in the previous 12 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Blinded study arm
- 2 (Type: EXPERIMENTAL): Blinded study arm
- 3 (Type: EXPERIMENTAL): Blinded study arm
- 4 (Type: EXPERIMENTAL): Blinded study arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes treated with ≥1 glucose-lowering medication for at least 12 months~* UACR 200 to 3000 mg/g~* eGFR ≥30 ml/min/1.73m2~* Treated with at least the minimal recommended dose of an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin II receptor blocker (ARB), but not both~Exclusion Criteria:~* History of Type 1 diabetes~* Women who are breast feeding~* Treatment with any uric acid-lowering therapy within previous 2 weeks~* History of intolerance to any XO (xanthine oxidase) inhibitor~* History of a gout flare requiring pharmacologic treatment~* History or presence of tophaceous gout~* History of immunosuppressant treatment for any known or suspected renal disorder~* History of a non-diabetic form of renal disease~* Glycosylated hemoglobin (HbA1c) \>11%~* sUA \<4.0 mg/dL or \>10.0 mg/dL~* Positive urinary pregnancy test~* Dialysis for acute renal failure within previous 6 months~* Renal allograft in place or a scheduled kidney transplant within the next 22 weeks~* Congenital or acquired solitary kidney

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TMX-049 40 mg QD (Once Daily) (Type: EXPERIMENTAL): TMX-049: 40 mg of TMX-049 to be taken orally, once daily
- TMX-049 200 mg QD (Once Daily) (Type: EXPERIMENTAL): TMX-049: 200 mg of TMX-049 to be taken orally, once daily
- TMX-049 Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S9701 Paclitaxel in Treating Patients With Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed advanced ovarian epithelial, fallopian tube, or primary peritoneal cancer Must have undergone an initial exploratory laparotomy with tumor debulking AND Must be FIGO stage IIIA, IIIB, IIIC, or IV at the time of initial laparotomy Must have attained a clinically defined complete remission (CR) following treatment with platinum (cisplatin or carboplatin) and paclitaxel based combination chemotherapy regimen by achieving the following: No evidence of cancer on physical examination CA-125 no greater than 35 units/mL Creatinine no greater than 2.0 mg/dL OR Creatinine clearance greater than 60 mL/min Bilirubin no greater than 2.0 mg/dL Negative ascites No evidence of residual cancer on CT scan of the abdomen/pelvis or chest x-ray (or chest CT scan, if performed) No symptoms felt to be secondary to persistent malignancy Must have received a minimum of 5 and a maximum of 6 courses of chemotherapy prior to study Must register for study within 21 to 56 days after prior chemotherapy Not concurrently registered to SWOG-S9618, SWOG-S9619, SWOG-S9912, or SWOG-S0009 or front line treatment phase III GOG trials~PATIENT CHARACTERISTICS: Age: Any age Performance status: SWOG 0-2 Life expectancy: Not specified Hematopoietic: Granulocyte count at least 1,200/mm3 Platelet count at least 100,000/mm3 Hepatic: See Disease Characteristics Renal: See Disease Characteristics Other: No prior malignancy within past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or incidental carcinoid~PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent antitumor treatment No concurrent immunotherapy Chemotherapy: See Disease Characteristics Recovered from prior chemotherapy Prior cisplatin allowed if initial dose at least 50 mg/m2 Prior carboplatin allowed if initial dose at least 300 mg/m2 or AUC at least 4 No other concurrent chemotherapy Endocrine therapy: No concurrent hormonal therapy Radiotherapy: No concurrent radiotherapy No prior abdominal/pelvic irradiation Surgery: See Disease Characteristics No second look laparotomy or laparoscopy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- paclitaxel 3 cycles (Type: ACTIVE_COMPARATOR): paclitaxel given for 3 cycles
- paclitaxel for 12 cycles (Type: EXPERIMENTAL): paclitaxel given for 12 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written informed consent or assent~* Subject has completed study TR02-108, and has been compliant with the study protocol~* Women of childbearing potential must agree to use reliable methods of contraception for the duration of the study~Key Exclusion Criteria:~* Subject met any of the listed criteria for study drug discontinuation in protocol TR02-108.~* Abnormal laboratory assessments including LFT (≥ 3× upper limit of normal \[ULN\]), serum creatinine (\> 2× ULN) and absolute neutrophil count \[ANC\] (\< 1000).~* Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements.~* History of alcohol, medication or illicit drug abuse within the 6 months prior to consent.~* Smoking tobacco or any substance within 6 months prior to consent or anticipated inability to refrain from smoking throughout the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LAI (Type: EXPERIMENTAL): 590 mg LAI QD via a PARI Investigational eFlow® Nebulizer System (eFlow®) for 28 days followed by a 28-day off-treatment period. This cycle (28 days on treatment, 28 days off treatment) was to be repeated for up to 12 cycles, divided into 2 periods of 6 cycles each (approximately 12 months each).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison Across Treatment Conditions to Reduce Smokeless Tobacco Use

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* No interest in stopping ST use within 90 days of study entry~* Daily use of ST in the 6 months prior to study entry~Exclusion Criteria:~* Current use of tobacco or nicotine products, other than ST~* Current unstable medical and mental health conditions~* Use of any medication that may affect tobacco use or be affected by a reduction in tobacco use~* Pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Usual Care Group (Type: ACTIVE_COMPARATOR): Usual care for cessation with immediate quit date scheduled and two weeks of nicotine patch supplied.
- Reduction Group (Type: EXPERIMENTAL): Reduction in nicotine exposure for 6 weeks prior to quit date using medicinal nicotine lozenge or reduced nicotine smokeless tobacco.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of Conventional 1.5 and 3.0T MR Images With Synthetically Reconstructed MR Images

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Subjects must:~1. Be an adult 18 years of age or older;~2. Have clinical indication for MRI of the brain according to the site standard of care;~3. If female of childbearing potential (not surgically sterile or post-menopausal), be determined non-pregnant by a medically qualified investigator or demonstrated non-pregnant by negative urine pregnancy test;~4. Be able to hear and understand instructions without assistive devices;~5. Have necessary mental capacity to understand instructions be able to comply with protocol requirements;~6. Are able and willing to provide written informed consent by signing the informed consent form (ICF).~Exclusion Criteria:~Subjects will be excluded that:~1. Were previously enrolled in this evaluation;~2. Have metallic/conductive or electrically/magnetically active implants or attached medical devices (except for dental devices/fillings, surgical clips, and surgical staples) that could be unsafe for MRI;~3. Have contraindication(s) to MRI scanning per the routine MR Safety Screening policy of the investigational site;~4. Have severe trauma or pre-existing pathology that is expected to interfere with normal conduct of MR scanning or complete scanning of the brain;~5. Have medical condition(s) such as those requiring urgent medical care that, in the opinion of a physician Investigator, would prevent safe participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Neurological MRI (Type: EXPERIMENTAL): Images acquired for post processing with synthetic software. This is a crossover design where all subjects receive the same imaging scan, and comparison is done between the raw conventional scan and post-processed images using the research software.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete